Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada.

[1]  N. Fairbairn,et al.  Measures to support a safer drug supply , 2020, Canadian Medical Association Journal.

[2]  T. Kerr,et al.  Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study , 2020, Drug and Alcohol Dependence.

[3]  A. Slaunwhite,et al.  Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada , 2020, Canadian Medical Association Journal.

[4]  M. Tyndall.  A safer drug supply: a pragmatic and ethical response to the overdose crisis , 2020, Canadian Medical Association Journal.

[5]  R. Hogg,et al.  Overdose Risk and Acquiring Opioids for Nonmedical Use Exclusively from Physicians in Vancouver, Canada , 2020, Substance use & misuse.

[6]  Marian Buhociu,et al.  Not what the doctor ordered: Motivations for nonmedical prescription drug use among people who use illegal drugs. , 2020, The International journal on drug policy.

[7]  Brandon del Pozo,et al.  Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths , 2020, Journal of Law, Medicine & Ethics.

[8]  C. Michael White.  Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States. , 2020, Journal of the American Pharmacists Association : JAPhA.

[9]  C. Strike,et al.  Practices of care among people who buy, use, and sell drugs in community settings , 2020, Harm Reduction Journal.

[10]  T. Kerr,et al.  A Low-Barrier and Comprehensive Community-Based Harm-Reduction Site in Vancouver, Canada. , 2020, American journal of public health.

[11]  S. Martins,et al.  On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. , 2020, Drug and alcohol dependence.

[12]  J. Trafton,et al.  Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation , 2020, BMJ.

[13]  Ty S. Schepis,et al.  Prescription Opioid Misuse Motives in US Older Adults. , 2019, Pain medicine.

[14]  S. Martins,et al.  "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. , 2019, The International journal on drug policy.

[15]  E. Wood,et al.  Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? , 2019, Substance Abuse Treatment, Prevention, and Policy.

[16]  M. Asbridge,et al.  The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review , 2019, BMC Health Services Research.

[17]  Ramzi W. Nahhas,et al.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. , 2019, Drug and alcohol dependence.

[18]  J. Gagne,et al.  Association of Opioid Overdose With Opioid Prescriptions to Family Members. , 2019, JAMA internal medicine.

[19]  Philip R. Kavanaugh,et al.  "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion. , 2019, The International journal on drug policy.

[20]  T. Kerr,et al.  "We don't got that kind of time, man. We're trying to get high!": Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs. , 2019, The International journal on drug policy.

[21]  JoAnna M Scott,et al.  Mortality After Discontinuation of Primary Care–Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study , 2019, Journal of General Internal Medicine.

[22]  J. Montaner,et al.  Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis. , 2019, Spatial and spatio-temporal epidemiology.

[23]  William J. Parish,et al.  Opioid medication discontinuation and risk of adverse opioid-related health care events. , 2019, Journal of substance abuse treatment.

[24]  S. Barbic,et al.  Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. , 2019, The American journal on addictions.

[25]  B. Marshall,et al.  Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. , 2019, The International journal on drug policy.

[26]  T. Kerr,et al.  Trusting the source: The potential role of drug dealers in reducing drug-related harms via drug checking. , 2019, Drug and alcohol dependence.

[27]  M. Socías,et al.  Successful Treatment with Slow-Release Oral Morphine following Afentanyl-Related Overdose: A Case Report , 2019, Substance abuse.

[28]  Christopher M. Jones,et al.  Correlates of Prescription Opioid Use, Misuse, Use Disorders, and Motivations for Misuse Among US Adults. , 2018, The Journal of clinical psychiatry.

[29]  Fang Zhang,et al.  Four States With Robust Prescription Drug Monitoring Programs Reduced Opioid Dosages. , 2018, Health affairs.

[30]  H. Knudsen,et al.  Perceptions and practices addressing diversion among US buprenorphine prescribers. , 2018, Drug and alcohol dependence.

[31]  T. Rummans,et al.  How Good Intentions Contributed to Bad Outcomes: The Opioid Crisis , 2018, Mayo Clinic proceedings.

[32]  Mark Edmund Rose,et al.  Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts , 2017, Pain medicine.

[33]  Martin A Makary,et al.  Overprescribing is major contributor to opioid crisis , 2017, British Medical Journal.

[34]  T. Cicero,et al.  The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse , 2017, Dialogues in clinical neuroscience.

[35]  T. Green,et al.  Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. , 2017, The International journal on drug policy.

[36]  Corey S Davis,et al.  Today's fentanyl crisis: Prohibition's Iron Law, revisited. , 2017, The International journal on drug policy.

[37]  Daniel Ciccarone,et al.  Fentanyl in the US heroin supply: A rapidly changing risk environment. , 2017, The International journal on drug policy.

[38]  Jeff Powell,et al.  An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services , 2017, Harm Reduction Journal.

[39]  M. Rothstein.  The Opioid Crisis and the Need for Compassion in Pain Management. , 2017, American journal of public health.

[40]  Scott P. Novak,et al.  Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health. , 2017, Addictive behaviors.

[41]  S. Martins,et al.  Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014. , 2017, Addictive behaviors.

[42]  Traci C. Green,et al.  Counterfeit Medications and Fentanyl. , 2016, JAMA internal medicine.

[43]  M. Schechter,et al.  Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial. , 2016, JAMA psychiatry.

[44]  Grant T Baldwin,et al.  Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. , 2016, The New England journal of medicine.

[45]  S. Wilczyński.  The use of dynamic thermal analysis to distinguish between genuine and counterfeit drugs. , 2015, International journal of pharmaceutics.

[46]  R. Pacula,et al.  How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D , 2015, Journal of health economics.

[47]  Peter Kreiner,et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. , 2015, Annual review of public health.

[48]  S. Weiner,et al.  Mandatory use of prescription drug monitoring programs. , 2015, JAMA.

[49]  Julio S. G. Montaner,et al.  Denial of prescription analgesia among people who inject drugs in a Canadian setting. , 2015, Drug and alcohol review.

[50]  Maria A. Levi-Minzi,et al.  Under treatment of pain: a prescription for opioid misuse among the elderly? , 2013, Pain medicine.

[51]  John W. Murphy,et al.  Understanding the Etiology of Prescription Opioid Abuse , 2013, Qualitative health research.

[52]  K. Silva,et al.  Prescription Drug Misuse and Risk Behaviors Among Young Injection Drug Users , 2013, Journal of psychoactive drugs.

[53]  R. T. Furst.  Suboxone Misuse Along the Opiate Maintenance Treatment Pathway , 2013, Journal of addictive diseases.

[54]  R. Carlson,et al.  "I'm not afraid of those ones just 'cause they've been prescribed": perceptions of risk among illicit users of pharmaceutical opioids. , 2012, The International journal on drug policy.

[55]  É. Roy,et al.  The Growing Popularity of Prescription Opioid Injection in Downtown Montréal: New Challenges for Harm Reduction , 2011, Substance use & misuse.

[56]  Gladys E. Ibañez,et al.  Motivations for non-medical prescription drug use: a mixed methods analysis. , 2010, Journal of substance abuse treatment.

[57]  M. Agar,et al.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. , 2009, The American journal on addictions.

[58]  S. McCabe,et al.  Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. , 2007, Addictive behaviors.

[59]  R. Allard,et al.  Predictors of methadone program non-retention for opioid analgesic dependent patients. , 2013, Journal of substance abuse treatment.

[60]  Bruce D. Johnson,et al.  Prescription opioid use, misuse, and diversion among street drug users in New York City. , 2008, Drug and alcohol dependence.

[61]  Anselm L. Strauss,et al.  Basics of qualitative research : techniques and procedures for developing grounded theory , 1998 .